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This issue of the European Journal of Nuclear Medicine
and Molecular Imaging contains a series of studies
comparing the in vitro and in vivo characteristics of a
series of 12 cholecystokinin (CCK) receptor (CCKR)
binding ligands [1–3]. Nine European research groups
from Athens, Basel, Freiburg, Innsbruck, Ljubljana, Lon-
don, Naples, Nijmegen and Rotterdam supported by a
COST Action (BM0607) of the European Union have
cooperated to carry out these studies. The project aimed to
evaluate the in vitro and in vivo properties of 12 DOTA-
conjugated CCK2R ligands. The ligands were synthesized
by the groups in Athens, Freiburg, Innsbruck, Nijmegen,
London and Ljubljana and the following characteristics of
the ligands were studied in standardized model systems:
– The affinity (IC50) of the ligands for the CCK2R was
determined in Berne
– The internalization kinetics of the ligands were
determined in Naples and in Rotterdam
– The stability of the ligands was evaluated in Innsbruck
– The in vivo targeting properties of CCK2R-expressing
tumours were evaluated in Nijmegen and in London
CCK/gastrin analogues were first proposed for radionu-
clide imaging and therapy of tumours approximately
15 years ago. The name of the late Thomas Behr is
inextricably connected to the in vivo use of CCK/gastrin
analogues for in vivo targeting of CCK2R-expressing
tumours (Fig. 1). Thomas Behr recognized the fact that
excellent sensitivity of the pentagastrin test for detecting
malignant C cells in patients with medullary thyroid
carcinoma (MTC) suggested a high incidence of gastrin
receptors in human MTC [4]. Indeed, at that time the
autoradiography studies of Reubi et al. confirmed the
expression of CCK/gastrin receptor in more than 90% of
MTCs and in several other tumour types, such as small cell
lung cancer, stromal ovarian cancers and astrocytomas [5].
At that time Thomas Behr worked at the Department of
Nuclear Medicine at the Georg-August University in
Göttingen headed by the late Prof. Wolfgang Becker. There
he showed that a 131I-labelled truncated gastrin analogue
accumulated specifically in CCK2R-expressing tumours in
mice and men [4]. In a subsequent study Thomas Behr
screened a series of 20(!) CCK/gastrin analogues [6]. All
peptides were radioiodinated and the affinity for the CCK2R
was determined and a few of these peptides were tested in
nude mice with CCK2R-expressing xenografts. From these
studies Thomas Behr selected minigastrin, a 12-amino acid
peptide containing the pentaglutamic acid sequence as the
optimal peptide for targeting CCK2R-expressing tumours.
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Thomas realized that for in vivo application these internal-
izing peptides should be labelled with a residualizing
radiolabel and therefore, minigastrin was conjugated with
DTPA and labelled with 111In and tested in xenografted nude
mice and in a patient with MTC.
Ever since Thomas Behr carried out this pioneering
work numerous research groups have synthesized new
CCK/gastrin analogues in an attempt to further improve the
tumour targeting properties. As part of the COST Action
BM0607 on targeted radionuclide therapy we designed a set
of in vitro and in vivo studies to select the peptides with
optimal characteristics for in vivo targeting (Table 1). The
group of Prof. Reubi in Berne, Switzerland determined the
affinity of each of the 12 peptide analogues for the CCK2R
using in vitro competitive autoradiography. This study
showed that the IC50 of all ligands was in the nanomolar
range (0.2–3.4 × 10−9 M). The internalization kinetics of
the 12 peptides as determined in Rotterdam and in Naples
were also similar with most of the radiolabelled peptides
internalized within 2 h [2].
A successful ligand for targeted radionuclide therapy
should be stable in vivo at least during hours. Therefore the
biological stability of the 12 analogues was studied in detail
by the group in Innsbruck [3]. Variable stability in human
serum was found for the different peptides with calculated
half-lives between 4.5±0.1 and 198±0.1 h. In urine of
normal mice only metabolized peptide fragments were
detected even at short times after injection for all peptides.
Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) revealed a major
cleavage site of all minigastrin derivatives between Asp and
Phe-NH2 at the C-terminal end of the peptides.
The in vivo properties of the 12 radiolabelled peptides
were studied in Nijmegen and in London. The Nijmegen
group determined the biodistribution of the 111In-labelled
peptides in mice with subcutaneous CCK2/gastrin receptor-
expressing tumours in the flank and with receptor-negative
tumours contralaterally [1]. The two CCK analogues both
displayed relatively low tumour uptake as compared to the
ten minigastrin analogues. Two linear minigastrin peptides
displayed good accumulation in the CCK2R+ tumour, but
with very high kidney uptake. The linear analogue lacking
the penta-Glu sequence (MG11) showed lower tumour
uptake and also low kidney uptake. Varying the N-terminal
Glu residues in the minigastrin analogues led to
improved tumour targeting properties, with the analogue
in which D-amino acids were used in the pentaglutamic
acid sequence (PF11), displaying high tumour uptake in
combination with low retention in the kidneys. Further-
more these studies showed that the cyclized peptide and
the divalent peptide also showed high tumour to kidney
ratios in this animal model. In addition, the group in
London studied the in vivo tumour targeting properties of
the 12 peptides by microSPECT/CT imaging. SCID mice
with A431-CCK2R-positive and A431-CCK2R-negative
tumours on the left and right shoulders, respectively, were
injected with the 111In-labelled minigastrin/CCK peptide
analogues radiolabelled with 111In to a specific activity of
30 MBq/nmol. Whole-body SPECT/CT images after 1 and
4 h were obtained with a four-head microSPECT scanner
equipped with 2-mm pinhole collimators. All images
obtained showed preferential uptake in the CCK2R-
expressing tumours. Peptides were ranked based on the
quantitation of tumour, kidney uptake and retention in the
tumour during 4 h. Four compounds appeared to have optimal
properties for therapeutic application: the cyclic gastrin
analogue, two minigastrin analogues (PP-F11 and PP-F16)
and the dimeric compound MGD5.
In summary, in the studies described in this issue of the
European Journal of Nuclear Medicine and Molecular
Table 1 Nomenclature, sequence and molecular weight of the 12 CCK2R binding ligands that were evaluated in the project
Name Sequence MW (g/mol)
G-CCK8 DOTA-Gly-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2 1,507.0
SA106 DOTA-DAsp-Phe(p-CH2SO3H)-HPG-Gly-Trp-HPG-Asp-Phe-NH2 1,482.6
MG0 DOTA-DGlu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,037.0
Sargastrin DOTA-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 2,483.6
MG11 DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1,531.0
APH070 DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1,677.8
PP-F10 DOTA-DGln-DGln-DGln-DGln-DGln-DGln-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,042.9
PP-F6 DOTA-DGln-DGln-DGln-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 1,658.7
PP-F16 DOTA-DGln-DGlu-DGln-DGlu-DGln-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,045.9
PP-F11 DOTA-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 2,048.8
Cyclo-MG2 DOTA-DGlu-(Ala-Tyr)-DLys-Trp-Nle-Asp-Phe-NH2 (cyclo DGlu-DLys) 1,455.7
MGD5 DOTA-Gly-Ser-Cys-(Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2)2 2,782.9
HPG homopropargyl glycine
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Imaging the in vitro [2, 3] and in vivo [1] properties of a
series of 12 CCK2R binding ligands were determined
extensively. The studies indicated that three of these
analogues have optimal characteristics for application in
targeted radionuclide therapy of CCK2R-expressing can-
cers. In future studies the groups will further investigate the
therapeutic potential of the selected compounds in mouse
tumour models. Based on these studies a set of new ligands
will be designed and synthesized. In addition, a working
group aims to transfer one of these compounds for clinical
studies in cancer patients. In conclusion, 15 years after the
pioneering work of Thomas Behr, his gastrin analogues will
be applied clinically for radionuclide imaging and possibly
for radionuclide therapy.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
References
1. Laverman P, Joosten L, Eek A, Roosenburg S, Peitl PK, Maina T,
et al. Comparative biodistribution of 12 (111)In-labelled gastrin/
CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging,
doi:10.1007/s00259-011-1806-0.
2. Aloj L, AurilioM, Rinaldi V, D’ambrosio L, Tesauro D, Peitl PK, et al.
Comparison of the binding and internalization properties of 12 DOTA-
coupled and (111)In-labelled CCK2/gastrin receptor binding peptides:
a collaborative project under COSTAction BM0607. Eur J Nucl Med
Mol Imaging, doi:10.1007/s00259-011-1816-y.
3. Ocak M, Helbok A, Rangger C, Peitl PK, Nock BA, Morelli G, et al.
Comparison of biological stability and metabolism of CCK2 receptor
targeting peptides, a collaborative project under COSTBM0607. Eur J
Nucl Med Mol Imaging, doi:10.1007/s00259-011-1818-9.
4. Behr TM, Jenner N, Radetzky S, Béhe M, Gratz S, Yücekent S, et al.
Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical
and initial clinical evaluation of the diagnostic and therapeutic
potential of radiolabelled gastrin. Eur J Nucl Med 1998;25(4):424–30.
5. Reubi JC, Schaer JC,Waser B. Cholecystokinin(CCK)-A and CCK-B/
gastrin receptors in human tumors. Cancer Res 1997;57(7):1377–86.
6. Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, et al.
Radiolabeled peptides for targeting cholecystokinin-B/gastrin
receptor-expressing tumors. J Nucl Med 1999;40(6):1029–44.
Eur J Nucl Med Mol Imaging (2011) 38:1407–1409 1409
